The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each instance of overcharging.
It is the first 340B program violation letter that the U.S. Health Resources and Services Administration (HRSA) has sent to a drug manufacturer regarding contract pharmacy restrictions since October 2021. It also is the first such letter under the signature of HRSA Administrator Carole Johnson, who was appointed by U.S. Health and Human Services (HHS) Secretary Xavier Becerra in January.
The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each instance of overcharging.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
